title: Gastric cancers emerging after H. pylori eradication arise exclusively from non-acid-secreting areas.
abstract: Although Helicobacter pylori (H. pylori) eradication has some inhibitory effects on the subsequent development of gastric cancer, there are sporadic cases of gastric cancer even after successful eradication.  The pathogenesis of gastric cancer emerging after H. pylori eradication remains to be clarified.  In this study, employing Congo-red chromoendoscopy, which is capable of visualizing the acid-secreting fundic mucosa, we investigated the topographic relationship of the acid secretion pattern to the occurrence site of gastric cancers emerging after eradication.  Fourteen consecutive patients who suffered from new gastric cancer after eradication, defined as lesions that were discovered at least 2 years after the eradication, were prospectively enrolled.  Whether the neoplasias arose from acid-secreting or non-acid-secreting areas was evaluated with Congo-red chromoendoscopy.  Biopsy specimens taken from the two areas were subjected to histologic evaluation and immunohistochemistry for Ki-67 and p53.  The mean period from the eradication to the subsequent occurrence of gastric cancer was 74 (44) months.  There were two cancer lesions in 5 cases, and thus there was a total 19 lesions from 14 cases.  Congo-red chromoendoscopy revealed that all 19 lesions arose exclusively from non-acid-secreting areas.  Histological examination revealed sustained hyperproliferation and accumulation of p53 protein was frequently detectable in non-acid-secreting areas.  Genetic alteration such as p53 mutation seems to be already present in the residual non-acid-secreting areas after eradication, areas that could be the origin of gastric carcinogenesis after eradication.  Identification of such high-risk areas should be a promising approach for estimating the individual cancer risk after eradication.
authors.affiliation: Division of Gastroenterology, Tohoku University Graduate School of Medicine, Aobaku, Sendai, Japan. kiijima@med.tohoku.ac.jp
authors.forename: Katsunori
authors.initials: K
authors.lastname: Iijima
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Abe
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Koike
authors.forename: Kaname
authors.initials: K
authors.lastname: Uno
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Endo
authors.forename: Waku
authors.initials: W
authors.lastname: Hatta
authors.forename: Naoki
authors.initials: N
authors.lastname: Asano
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Asanuma
authors.forename: Akira
authors.initials: A
authors.lastname: Imatani
authors.forename: Tooru
authors.initials: T
authors.lastname: Shimosegawa
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003224:Congo Red; D016099:Endoscopy, Gastrointestinal / Q000379:methods; D005753:Gastric Mucosa / Q000378:metabolism / Q000382:microbiology / Q000473:pathology*; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006652:Histological Techniques; D006801:Humans; D007150:Immunohistochemistry; D007564:Japan; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D020116:Pepsinogen A / Q000097:blood; D011446:Prospective Studies; D018709:Statistics, Nonparametric; D013274:Stomach Neoplasms / Q000382:microbiology* / Q000473:pathology*
chemical_list: D000900:Anti-Bacterial Agents; D003224:Congo Red; D020116:Pepsinogen A